Safety, Tolerability and Pharmacokinetics Study in Patients with Pulmonary Arterial Hypertension (PAH) Temporarily Switching from Oral to IV Selexipag

被引：3
|
作者：
Klose, H. [1 ]
Chin, K. [2 ]
Ewert, R. [3 ]
Gall, H. [4 ]
Parambil, J. [5 ]
Poch, D. [6 ]
Seyfarth, H. [7 ]
Axelsen, L. [8 ]
Schmitz, S. Hsu [9 ]
Stein, C. [10 ]
Preston, I. [11 ]
机构：
[1] Univ Med Ctr Hamburg Eppendorf, Dept Resp Med, Ctr Oncol, Hamburg, Germany
[2] Univ Texas Southwestern Med Ctr Dallas, Dallas, TX 75390 USA
[3] Ernst Moritz Arndt Univ Greifswald, Dept Resp Med, Clin Internal Med, Greifswald, Germany
[4] UGMLC, Internal Med, Giessen, Germany
[5] Cleveland Clin, Dept Pulm Allergy & Crit Care Med, Resp Inst, Cleveland, OH 44106 USA
[6] Univ Calif San Diego, Dept Pulm Crit Care, San Diego, CA 92103 USA
[7] Univ Leipzig, Dept Resp Med, Leipzig, Germany
[8] Actel Pharmaceut Ltd, Clin Pharmacol, Allschwil, Switzerland
[9] Actel Pharmaceut Ltd, Biostat, Allschwil, Switzerland
[10] Actel Pharmaceut Ltd, Clin Sci, Allschwil, Switzerland
[11] Tufts Univ, Sch Med, Tufts Med Ctr, Pulm Crit Care & Sleep Div, Boston, MA 02111 USA
来源：
JOURNAL OF HEART AND LUNG TRANSPLANTATION | 2019年 / 38卷 / 04期
关键词：
D O I：
10.1016/j.healun.2019.01.1247
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
1237
引用
收藏
页码：S490 / S490
页数：1
相关论文
共 50 条
  • [1] Temporarily switching from oral to intravenous selexipag in patients with pulmonary arterial hypertension: safety, tolerability, and pharmacokinetic results from an open-label, phase III study
    Hans Klose
    Kelly M. Chin
    Ralf Ewert
    Henning Gall
    Joseph Parambil
    David Poch
    Hans-Jürgen Seyfarth
    Lene N. Axelsen
    Shu-Fang Hsu Schmitz
    Claudia Stein
    Ioana R. Preston
    Respiratory Research, 22
  • [2] Temporarily switching from oral to intravenous selexipag in patients with pulmonary arterial hypertension: safety, tolerability, and pharmacokinetic results from an open-label, phase III study
    Klose, Hans
    Chin, Kelly M.
    Ewert, Ralf
    Gall, Henning
    Parambil, Joseph
    Poch, David
    Seyfarth, Hans-Jurgen
    Axelsen, Lene N.
    Schmitz, Shu-Fang Hsu
    Stein, Claudia
    Preston, Ioana R.
    RESPIRATORY RESEARCH, 2021, 22 (01)
  • [3] Individualized Dosing of Selexipag Based on Tolerability in the GRIPHON Study Shows Consistent Efficacy and Safety in Patients With Pulmonary Arterial Hypertension (PAH)
    Channick, Richard
    Chin, Kelly
    Di Scala, Lilla
    Frey, Aline
    Preiss, Ralph
    Gaine, Sean
    Galie, Nazzareno
    Ghofrani, Hossein Ardeschir
    Hoeper, Marius
    Lang, Irene
    McLaughlin, Vallerie
    Rubin, Lewis
    Simonneau, Gerald
    Sitbon, Olivier
    Tapson, Victor
    CHEST, 2015, 148 (04)
  • [4] TRANSITION OF IV TREPROSTINIL TO ORAL SELEXIPAG IN PULMONARY ARTERIAL HYPERTENSION
    Mahoney, Roshan
    Sweidan, Alexander
    Yaghmour, Bassam
    CHEST, 2021, 160 (04) : 2229A - 2229A
  • [5] Safety and tolerability of transition from inhaled treprostinil to oral selexipag in pulmonary arterial hypertension: Results from the TRANSIT-1 study
    Frost, Adaani
    Janmohamed, Munir
    Fritz, Jason S.
    McConnell, John W.
    Poch, David
    Fortin, Terry Ann
    Miller, Chad E. g
    Chin, Kelly M.
    Fisher, Micah
    Eggert, Michael
    McEvoy, Colleen
    Benza, Raymond L.
    Farber, Harrison W.
    Kim, Nick H.
    Pfister, Thomas
    Shiraga, Yoko
    McLaughlin, Vallerie
    JOURNAL OF HEART AND LUNG TRANSPLANTATION, 2019, 38 (01): : 43 - 50
  • [6] Tolerability And Safety Of Transition From Inhaled Treprostinil To Oral Selexipag In Pulmonary Arterial Hypertension: Results From The Transit-1 Study
    Frost, A. E.
    Janmohamed, M.
    Fritz, J.
    McConnell, J. W.
    Poch, D.
    Fortin, T.
    Miller, C.
    Chin, K.
    Fisher, M. R.
    Eggert, M.
    McEvoy, C.
    Benza, R. L.
    Farber, H. W.
    Kim, N. H.
    Hartline, B.
    Pfister, T.
    Shiraga, Y.
    McLaughlin, V.
    AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2017, 195
  • [7] Efficacy and safety of selexipag in pulmonary arterial hypertension (PAH) patients with and without significant cardiovascular (CV) comorbidities
    Rosenkranz, S.
    Channick, R.
    Chin, K.
    Jenner, B.
    Gaine, S.
    Galie, N.
    Ghofrani, H. A.
    Hoeper, M. M.
    McLaughlin, V. V.
    Preiss, R.
    Rubin, L. J.
    Simonneau, G.
    Sitbon, O.
    Tapson, V.
    Lang, I. M.
    EUROPEAN HEART JOURNAL, 2019, 40 : 3038 - 3038
  • [8] Efficacy and safety of selexipag in pulmonary arterial hypertension (PAH) patients with and without significant cardiovascular (CV) comorbidities
    Rosenkranz, S.
    Channick, R.
    Chin, K.
    Jenner, B.
    Gaine, S.
    Galie, N.
    Ghofrani, H. A.
    Hoeper, M. M.
    McLaughlin, V
    Preiss, R.
    Rubin, L.
    Simonneau, G.
    Sitbon, O.
    Tapson, V
    Lang, I
    PNEUMOLOGIE, 2020, 74 : S62 - S63
  • [9] Safety, tolerability and pharmacokinetics of an intravenous bolus of sildenafil in patients with pulmonary arterial hypertension
    Vachiery, Jean-Luc
    Huez, Sandrine
    Gillies, Hunter
    Layton, Gary
    Hayashi, Naoto
    Gao, Xiang
    Naeije, Robert
    BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 2011, 71 (02) : 289 - 292
  • [10] Safety and Tolerability of LIQ861 in Pulmonary Arterial Hypertension (PAH): Results from INSPIRE Study
    Hill, N. S.
    Feldman, J. P.
    Sahay, S.
    Levine, D. J.
    Patel, S.
    Galloway, A.
    Bull, T. M.
    AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2022, 205
12345